• HIT-SIOP PNET 4 a prospective randomized controlled trial of hyperfractionated versus conventionally fractionated radiotherapy in standard risk medulloblastoma. (chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • Protocollo di diagnosi e cura del medulloblastoma metastatico e/o a istologia sfavorevole (HART)
  • 2° protocollo AIEOP di diagnosi e cura degli ependimomi dell'età pediatrica
  • SIOP-LGG 2004 cooperative multicenter study for children and adolescents with low grade glioma
  • Protocol CLDE225C2301 Novartis: A Phase III, multi-center, open-label, randomized,controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma.
  • Protocol for treatment of CNS high risk malignant tumors in patients aged < 3 years
  • BO25041 / ITCC-019 / HGG-01: An open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma.
  • Studio epidemiologico "MOBI-KIDS - Rischio di tumori cerebrali ed esposizione a campi elettromagnetici a radiofrequenza nei bambini e negli adolescenti: uno studio multicentrico internazionale.
  • European Rhabdoid Registry - EU-RHAB.
  • SIOP CNS GCT II: prospective trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours.

  • AIEOP EURO-LB 02 International protocol of the European Inter-group for Childhood Non-Hodgkin Lymphoma (EICNHL) for lymphoblastic lymphoma.(chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • AIEOP LNH 97 B protocollo multicentrico per la diagnosi e la terapia dei linfomi non Hodgkin (LNH) pediatrici B maturi (chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • AIEOP ALCL99 international protocol for diagnosis and treatment of anaplastic large cell lymphomas of childhood (chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • AIEOP ALCL-relapse, treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence
  • Intergroup trial for children or adolescents with B-Cell NHL or B-AL: Evaluation of rituximab efficacy and safety in high risk patients (Studio di Fase III)

  • AIEOP LH 2004
  • EuroNet-PHL-LP1: 1° Studio Internazionale per il Linfoma di Hodgkin, varietà prevalenza linfocitaria, nei bambini e negli adolescenti